Co announces new Phase 1 clinical data on its M.E.K inhibitor, ARRY-162, and its p38 inhibitor, ARRY-797. Array presented preliminary information on its M.E.K inhibitor, ARRY-162, from both a single ...
Shanghai Meiyue Biotech Development Co. Ltd. has discovered MAPK p38 inhibitors reported to be useful for the treatment of arthritis, psoriasis, systemic lupus erythematosus, diabetes, cancer, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results